Skip to Content

Fast-Acting Cyanide Antidote Could Help Disaster Victims

Parked ambulances

Chemical attacks, building fires, industrial accidents—in situations like these, where cyanide poisoning is a serious threat to a large number of people, every second counts. Fast treatment can mean the difference between life and death.

Unfortunately, cyanide antidotes on the market today require at least 15 minutes of an IV drip. During an emergency, that limits how many other people can be treated before it’s too late.

Researchers at the University of Minnesota are developing a new antidote that could give first responders a crucial edge in saving those exposed to cyanide poisoning. The drug, called Sulfanegen, quickly converts cyanide in the body into a less toxic compound. Sulfanegen is injectable, easier to administer than an IV, and takes effect in less than three minutes.

The antidote has been developed and refined over the last 10 years by three researchers from the U’s Center for Drug Design (CDD): Director Robert Vince, Ph.D.; Professor Steven Patterson, Ph.D.; and Adjunct Professor Herbert Nagasawa, Ph.D. In September, they received a patent for the newest formulation of the drug.

Patterson said the antidote is different from its predecessors in that it takes advantage of a different process in the body—one that normally serves to break down a common amino acid found in many foods.

“What we’re doing is exploiting a natural pathway—it’s kind of a housekeeping enzyme that’s there to take care of any excess of an amino acid called cysteine,” he said. “One of the steps in that pathway is capable of converting cyanide to a substance that’s far less toxic. If we provide the body with that intermediate compound from the pathway while cyanide is present, it will convert it to a less toxic substance extremely rapidly.”

It’s important to treat cyanide poisoning as soon as possible because the toxin itself acts quickly. Cyanide kills cells in the body by preventing them from using oxygen, which can cause convulsions, loss of consciousness, and death, according to the Centers for Disease Control and Prevention.

While people can encounter hazardous levels of cyanide while working in gold mines, laboratories, and other industrial settings, where cyanide levels can accumulate over time to cause long-term health problems, large disasters, such as chemical attacks and building fires, are where a fast-acting antidote is most important.

A Compact Dose, A Longer Shelf Life

Vince, Patterson, and Nagasawa have been developing the cyanide antidote for about 10 years now, supported during that time by federal CounterACT funding and CDD funds. Nagasawa, who originally conceived of the idea for the antidote, had recently retired when the time came to pursue it. He encouraged Patterson to take the lead on the project, but stayed closely involved throughout development, along with Vince. Nagasawa said early tests encouraged them to keep working.

“We had done some work initially on the antidote and it turned out that it worked pretty well,” he said.

From there, the researchers focused on making the antidote practical for field use. They whittled down the dose size to less than 3 milliliters of liquid—a small enough dose to be injected into the thigh. They also extended its shelf life to at least three years, ensuring the drug can be stored and kept on hand for when disaster strikes.

During development, the extensive expertise and capabilities within the Center for Drug Design enabled the team to create, test, and evaluate new formulations. For industry partners, these steps go a long way toward lowering the risk—and raising the appeal—of bringing the antidote to market, Vince said.

With help from experts at the U’s Office for Technology Commercialization, the researchers are now working with industry partners to develop a device for administering the antidote. The goal is to keep the drug easy to both store and administer, similar to the way an EpiPen is easy to keep on hand and use immediately in case of a life-threatening allergic reaction.

While the drug shows significant promise, it still has several steps to complete before it can be marketed for use, including clearing FDA regulations and being proven safe and effective for widespread use.

“Long term, what I hope is that this antidote ultimately gets approved and that, for the people who are exposed to cyanide, it saves their lives,” Patterson said.

Kevin Coss

Kevin Coss

Kevin is a communications specialist with the Office of the Vice President for Research.

coss@umn.edu

Latest Blog Posts

Chalkboard illustration showing new ideas and work leading to productivity

Early results from piloting a new way to manage Institutional Review Board submissions shows an improved turnaround time and increased employee engagement.

Read More
People work together in an office

MNSBIR guides startups and small businesses, including those based on U research, in applying for federal grants that help bring new innovations to market.

Read More
President Joan Gabel during an Inauguration Week event at McNamara Alumni Center.

Joan T.A. Gabel, the U's 17th president, emphasized the importance of the University research mission as part of her recent inaugural address.

Read More
Categories:
A student presents his research at a UMR poster fair

At UMN Rochester, in-course research experiences foster undergraduates' interest in science and help to prepare them for a successful career.

Read More